IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Trop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.

被引：0

作者：

Starodub, Alexander

Ocean, Allyson J.

Guarino, Michael J.

Picozzi, Vincent J.

Thomas, Salim Samuel

Messersmith, Wells A.

Shah, Manlsh A.

Vandat, Linda T.

Chuang, Ellen

Lin, Bruce S.

Govindan, Serengulam V.

Maliakal, Pius P.

Wegener, William A.

Hamburger, Steven A.

Sharkey, Robert M.

Goldenberg, David M.

机构：

[1] Indiana Univ, Hlth Goshen Ctr Canc Care, Goshen, IN USA

[2] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA

[3] Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA

[4] Virginia Mason Med Ctr, Seattle, WA 98101 USA

[5] Univ Florida, Hlth Canc Ctr, Orlando Hlth, Orlando, FL USA

[6] Univ Colorado Denver, Div Med Oncol, Aurora, CO USA

[7] Weill Cornell Med Coll, New York, NY USA

[8] Immunomedics Inc, Morris Plains, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.3032

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3032

引用

页数：1

共 44 条

[41] A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study.
Dotan, Efrat
Starodub, Alexander
Berlin, Jordan
Lieu, Christopher Hanyoung
Guarino, Michael J.
Marshall, John
Hecht, J. Randolph
Cohen, Steven J.
Messersmith, Wells A.
Maliakal, Pius P.
Wegener, William A.
Sharkey, Robert M.
Goldenberg, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[42] NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors-A phase 1/2 clinical trial.
Tolcher, Anthony W.
Meric-Bernstam, Funda
McKean, Meredith
Beerli, Roger R.
Waldmeier, Lorenz
Gebleux, Remy
Hellmann, Ina
Chrom, Pawel
Grawunder, Ulf
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[43] Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.
Shen, Lin
Zhou, Caicun
Meng, Xue
Sun, Yuping
Ji, Yinghua
Yang, Haihua
Ning, Fangling
Han, Liang
Jiang, Ou
Sun, Meili
Wen, Qing
Yu, Xinmin
Jia, Yuming
Huang, Hai
Zhao, Yanqiu
Zhang, Zhiye
Tian, Chuntao
Zhang, Zhen
Shi, Junwei
Cao, Guoqing
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[44] Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).
Richardson, Debra L.
Barve, Minal A.
Strauss, James Fredric
Ulahannan, Susanna Varkey
Moore, Kathleen N.
Hamilton, Erika Paige
Johnson, Melissa Lynne
Papadopoulos, Kyriakos P.
Zarwan, Corrine
Anderson, Charles K.
Buscema, Joseph
Doroshow, Deborah Blythe
Edenfield, William Jeffery
Matulonis, Ursula A.
Burns, Timothy F.
Huebner, Dirk
Jansen, Valerie Malyvanh
Mosher, Rebecca
Jarlenski, Donna
Tolcher, Anthony W.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →